Intensive chemotherapy and autologous hematopoietic stem cell mobilization, collection and transplantation with simultaneous Imatinib therapy in patients with blast crisis chronic myeloid leukaemia Treatment of patients with blastic phase chronic myeloid leukemia (CML) remains unsatisfactory. Imatinib mesylate, the most active monotherapy for CML in all phases of the disease, results in a median survival of patients with blastic phase CML of 6.9 months only. 1 Treatments combining Imatinib with conventional AML-or ALL-type chemotherapy are currently investigated for induction of remission in patients with blastic phase CML. Allogeneic hematopoietic stem cell transplantation (HSCT) is proposed in second chronic phase or at the time of minimal tumour burden if a suitable donor is available. Patients without a donor remain at high risk for rapid relapse.
High-dose chemotherapy with autologous HSCT in CML patients has been extensively studied during the decade preceding the Imatinib era. 2 Outcome after autologous HSCT depends mainly on the phase of the disease and on disease duration. Prospective randomized studies comparing autologous HSCT with conventional interferon-based treatment were initiated but remained nonconclusive. They were stopped when Imatinib therapy became available.
Autologous HSCT regained new interest as a theoretical concept of harvesting Ph-negative grafts in patients responding to Imatinib therapy. This concept was hampered with the observation of impaired growth of stem cell cultures in the presence of Imatinib and of myelotoxicity of Imatinib in some patients. Concerns about the viability of stem cells harvested under Imatinib therapy were raised. 3 The feasibility of mobilizing peripheral stem cells with rHu-G-CSF and simultaneous Imatinib therapy has now been demonstrated by several investigators. 4, 5 Cryopreservation of stem cells is performed routinely by several groups with the intention to use autologous HSCT with a graft containing a minimal amount of leukemic cells in the case of Imatinib failure and disease progression. So far, no reports exist on the use of those grafts.
We tested such an approach by combining continuous Imatinib therapy with intensive chemotherapy, mobilization and autologous HSCT. Results of three patients with CML in blast crisis document the feasibility (Table 1 ). The treatment consisted of Imatinib 600 mg qd combined with four cycles of cytarabine 1000 mg/m 2 per day for 7 consecutive days followed by autologous stem cell mobilization and apheresis and reinfusion of the graft after a high-dose chemo-/radiotherapy. Stem cells were mobilized after the fourth cycle of cytarabine by rHu-G-CSF at a dose of 10 mg/kg per day from day 10 on. CD34 þ cell count in the peripheral blood was monitored regularly. Apheresis, 15 l, with a Cobe Spectra cell separator was performed the day after the CD34 cell count in the peripheral blood reached 20 Â 10 6 /l. Cells were cryopreserved and reinfused after a conditioning therapy with either cyclophosphamide 200 mg/kg and busulfan 16 mg/kg (BuCy, for patients with myeloid blast crisis)(patient 2 þ 3) or cyclophosphamide 120 mg/kg plus 12 Gy TBI (Cy/TBI, for lymphoid blast crisis) (patient 1). Imatinib was given through all therapeutic procedures without a break.
Patient 1 was an 18-year-old male diagnosed with a primary lymphoid blast crisis CML in February 2004. Imatinib 600 mg qd was started immediately. After the second cycle of cytarabine a complete hematological remission (CHR), a complete cytogenetic remission (CCgR) and a 3.94 log reduction of BCR-ABL transcripts, as compared to BCR-ABL levels at diagnosis, were found. After the fourth cycle of cytarabine he was in ongoing CHR. BCR-ABL was detectable at stable low levels in the quantitative RT-PCR (Table 1) . After 5 days of mobilization stem cells were collected. BCR-ABL at a level comparable to the level in the peripheral blood at the time of stem cell harvest was detectable in the graft. The conditioning therapy consisted of Cy/TBI. 14.81 Â 10 6 /kg CD 34 þ cells were reinfused and engraftment was recorded on day 17. Imatinib therapy at a dose of 600 mg qd was carried on. At 3 and at 6 months post-transplant stable low-level BCR-ABL was detected while the patient was in CHR and CCgR (Table 1) . Relapse of lymphoid blast crisis was diagnosed in the bone marrow tap 6½ months post-transplant. Imatinib was stopped and the patient was enrolled in the BMS CA-180015 trial. Dasatinib at a dose of 70 mg bid was started. After 1 week he was hospitalized for unexplained dizziness and vertigo. He died 5 days after hospitalization with signs of brain herniation. The autopsy revealed a diffuse infiltration of the brain by lymphoblastoid cells.
Patient 2 is a 62-year-old male who was diagnosed with a primary myeloid blast crisis with over 90% blasts in the bone marrow analysis in August 2004. He was Philadelphia chromosome negative in conventional cytogenetic analysis with monosomy 18 in three of 25 metaphases. The PCR revealed the BCR-ABL transcript b3a2. In the FISH analysis, 21% of the cells had the BCR-ABL rearrangement. Imatinib 600 mg qd was started. After the third cycle of cytarabine CHR and complete molecular remission (CMolR, nested PCR negative) was recorded. The BCR-ABL-negative graft was reinfused after conditioning with Bu/Cy. At 6 months after the transplant he is in continuous CMolR.
The third patient is a 30-year-old female. In February 2004 a Ph þ CML in accelerated phase was diagnosed. She had 300 Â 10 9 /l leucocytes and 10% blasts in the peripheral blood. After cytoreduction with hydroxyurea Imatinib was started at a dose of 400 mg. After 4 months she had a CHR but only a minimal decline in BCR-ABL in the Q-RT-PCR. The Imatinib dose was increased to 600 mg qd. After 4 months she progressed to myeloid blast crisis with 30% blasts in the peripheral blood. Cytogenetics revealed new complex chromosomal aberrations. After the second cycle of cytarabine she was in CCgR and CMolR. Low-level BCR-ABL transcripts (2.85 log reduction as compared to the BCR-ABL level before therapy) were found again before autologous HSCT. The autologous stem cells were reinfused after Bu/Cy chemotherapy and engraftment took place on day 12. At 3 months after the autologous transplant she is in CCgR and BCR-ABL is below the detection limit in the Q-RT-PCR. This is the first report on the use of autologous stem cells that were mobilized, collected and reinfused during simultaneous Imatinib therapy in a series of three patients with CML blast crisis. This data shows the feasibility of an approach to reduce tumour load before harvesting autologous stem cells and then to reinfuse the graft after an additional high-dose chemotherapy and simultaneous Imatinib treatment. Harvest was successful after the first mobilization attempt in all patients. All stem cell products contained more than 2 Â 10 6 /kg CD34 þ cells with a minimal tumour load. Engraftment was rapid and no undue toxicity was recorded with full high-dose conditioning and despite simultaneous Imatinib treatment.
Our data extend previous reports on the mobilization with rHu-G-CSF and collection of autologous stem cells in patients simultaneously treated with Imatinib. Success rates of about 50% for the mobilization of sufficient CD34 þ cells with rHu-G-CSF alone and simultaneous Imatinib therapy in chronic phase CML patients have been reported. Longer disease duration may have a negative impact on successful CD34 þ cell mobilization. Two of our patients were newly diagnosed in CML blast crisis and stem cell collection occurred within 6 months of diagnosis. Stem cell harvest in the third patient took place 18 months after diagnosis of CML. Collection of a sufficient stem cell graft with simultaneous Imatinib treatment at a dose of 600 mg qd during the mobilization period was successful in all three patients mobilized within 18 months of diagnosis of blast crisis CML.
The autologous graft of one of our patient was BCR-ABL negative, a second graft had detectable BCR-ABL at low level in the Q-RT-PCR. No data on the presence of BCR-ABL is available for the third graft. Using an in vivo purging strategy with simultaneous Imatinib treatment during mobilization BCR-ABL negative grafts could not only be harvested from premobilization BCR-ABL-negative CML patients but in some cases even from BCR-ABL positive patients. 6 Perseghin et al. 7 tried to improve the in vivo purging efficacy by a dose increase of Imatinib 2 weeks before and during the mobilization procedure. Of 18 patients, nine failed the mobilization of sufficient CD34 þ cells in the first attempt. The authors concluded that this was possibly due to an inhibitory effect of Imatinib on the marrow stem cell compartment. Only one report on the use of autologous stem cells mobilized and collected with simultaneous Imatinib therapy has been published so far. 8 Imatinib therapy was stopped 31 days before autologous HSCT and the heavily pretreated patient had delayed engraftment, ANC reached 1 Â 10 9 /l on day 32. Engraftment of the transplants in our study patients was in the expected range of 12-18 days with continuous Imatinib therapy. No excessive toxicity during treatment was recorded.
Treatment of CML in BC with Imatinib combined with highdose cytarabine and autologous HSCT after high-dose chemo-/ radiotherapy was feasible early in the disease course and may result in complete molecular remission. Imatinib had no obvious deleterious effects on autologous stem cell mobilization, harvest and the engraftment of the autologous graft. This data form the basis for reconsidering the role of autologous HSCT in high risk but early CML. Acute lymphoblastic leukemia (ALL) is the most common malignant disease in children. Despite the high rates of remission induction and survival achieved with current treatment regimens, a subset of patients do not respond well to therapy. These patients either fail induction therapy or relapse after a short remission. The molecular basis for the refractory disease encountered in these patients has not been elucidated. Previous studies including ours have found that ALL cells may express certain cytokines, and that aberrant expression of endogenous cytokines such as tumor necrosis factor a (TNFa) may be associated with refractory disease. 1, 2 In our studies of two ALL cell lines differing in expression of endogenous TNF (enTNF), we have previously reported that enTNF expression was associated with resistance to recombinant (r) TNFa. 2 We later performed a series of studies on the phenotypes and drug sensitivity of these two lines (enTNF þ EU-1 and enTNF À EU-3), and found that although both EU-1 and EU-3 displayed similar immunophenotypes and certain molecular properties such as p53 status and expression of MDM2 and Bcl-2, only EU-1 was resistant to radiation-and doxorubicin-induced apoptosis.
3,4 As EU-1 but not EU-3 expresses a high level of enTNF, we hypothesized that enTNF may be one of the survival factors conferring resistance to radiation and doxorubicin.
Tumor necrosis factor a is a pleiotropic cytokine that exerts a wide variety of biological effects. In particular, TNFa can have proliferative and/or survival effects on 'normal' untransformed cells as well as some human tumor cells, as opposed to antiproliferative, apoptotic and cytotoxic effects on other tumors both in vitro and in vivo. 5 The biological activity of TNFa is mediated by binding of specific receptors expressed on the surface of multiple cell types. There are two types of TNF receptors (TNFR1 and TNFR2). TNFR1 mainly induces apoptotic signaling, whereas TNFR2 predominantly regulates survival signaling. The interaction between TNFa and TNFR2 results in binding of TNFR-associated factor 2 (TRAF2) and receptor interactive protein (RIP). Tumor necrosis factor receptor-associated factor 2 and RIP stimulate pathways leading to activation of survival signaling such as the NF-kB pathway. 6 Tumor necrosis factor a is also known to induce cell-survival signaling by activating the phosphatidylinositol-3 kinase (PI3K)-Akt (protein kinase B) pathway. 7 Activation of Akt entails a complex series of events involving additional proteins. Phosphatidylinositol-3 kinase-generated lipid products PI 3,4,5 P 3 and PI 3,4 P 2 recruit Akt to the plasma membrane, where the threonine 308 and serine 473 residues of Akt are phosphorylated and activated. Activated Akt exerts antiapoptotic effects through phosphorylation of substrates that directly regulate the apoptotic machinery such as Bad and caspase-9, or phosphorylation of substrates that indirectly inhibit apoptosis such as IKKa and MDM2. Unlike the pathway of NF-kB activation by TNFa, the mechanism for TNFa induction of the PI3k/Akt pathway remains largely unclear.
Studies have shown that certain neoplastic cells including ALL constitutively produce TNFa and that enTNF is associated with resistance to exogenous TNFa/rTNFa-induced cytotoxicity. enTNF þ tumor cells are resistant not only to rTNFa but also to chemotherapeutic drugs such as doxorubicin, and enTNF produced by neoplastic cells is associated with disease progression. The mechanisms for enTNF-induced cell survival and resistance to apoptosis are not yet clear. As TNFa can activate the PI3K-Akt pathway, we investigated whether the survival and antiapoptotic function of enTNF are through induction of PI3K-Akt.
The results of our studies on ALL cell lines indicate that enTNF is associated with activation of Akt. We examined EU-1 and
